BCMA-targeted immunotherapy for multiple myeloma

B cell maturation antigen (BCMA) is a novel treatment target for multiple myeloma (MM) due to its highly selective expression in malignant plasma cells (PCs). Multiple BCMA-targeted therapeutics, including antibody-drug conjugates (ADC), chimeric antigen receptor (CAR)-T cells, and bispecific T cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Bo, Jiang, Tianbo, Liu, Delong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7499842/
https://www.ncbi.nlm.nih.gov/pubmed/32943087
http://dx.doi.org/10.1186/s13045-020-00962-7
_version_ 1783583748169662464
author Yu, Bo
Jiang, Tianbo
Liu, Delong
author_facet Yu, Bo
Jiang, Tianbo
Liu, Delong
author_sort Yu, Bo
collection PubMed
description B cell maturation antigen (BCMA) is a novel treatment target for multiple myeloma (MM) due to its highly selective expression in malignant plasma cells (PCs). Multiple BCMA-targeted therapeutics, including antibody-drug conjugates (ADC), chimeric antigen receptor (CAR)-T cells, and bispecific T cell engagers (BiTE), have achieved remarkable clinical response in patients with relapsed and refractory MM. Belantamab mafodotin-blmf (GSK2857916), a BCMA-targeted ADC, has just been approved for highly refractory MM. In this article, we summarized the molecular and physiological properties of BCMA as well as BCMA-targeted immunotherapeutic agents in different stages of clinical development.
format Online
Article
Text
id pubmed-7499842
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-74998422020-09-21 BCMA-targeted immunotherapy for multiple myeloma Yu, Bo Jiang, Tianbo Liu, Delong J Hematol Oncol Review B cell maturation antigen (BCMA) is a novel treatment target for multiple myeloma (MM) due to its highly selective expression in malignant plasma cells (PCs). Multiple BCMA-targeted therapeutics, including antibody-drug conjugates (ADC), chimeric antigen receptor (CAR)-T cells, and bispecific T cell engagers (BiTE), have achieved remarkable clinical response in patients with relapsed and refractory MM. Belantamab mafodotin-blmf (GSK2857916), a BCMA-targeted ADC, has just been approved for highly refractory MM. In this article, we summarized the molecular and physiological properties of BCMA as well as BCMA-targeted immunotherapeutic agents in different stages of clinical development. BioMed Central 2020-09-17 /pmc/articles/PMC7499842/ /pubmed/32943087 http://dx.doi.org/10.1186/s13045-020-00962-7 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Yu, Bo
Jiang, Tianbo
Liu, Delong
BCMA-targeted immunotherapy for multiple myeloma
title BCMA-targeted immunotherapy for multiple myeloma
title_full BCMA-targeted immunotherapy for multiple myeloma
title_fullStr BCMA-targeted immunotherapy for multiple myeloma
title_full_unstemmed BCMA-targeted immunotherapy for multiple myeloma
title_short BCMA-targeted immunotherapy for multiple myeloma
title_sort bcma-targeted immunotherapy for multiple myeloma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7499842/
https://www.ncbi.nlm.nih.gov/pubmed/32943087
http://dx.doi.org/10.1186/s13045-020-00962-7
work_keys_str_mv AT yubo bcmatargetedimmunotherapyformultiplemyeloma
AT jiangtianbo bcmatargetedimmunotherapyformultiplemyeloma
AT liudelong bcmatargetedimmunotherapyformultiplemyeloma

Ejemplares similares